ABL SA group acquires Berlin based Medtech company Humedics
Reimbursement for the LiMAx® test - MEL Commission includes LiMAx® test in the MEL list 2022
Development of the new LiMAx® measurement device for determination of the liver function completed
German Institute for Health Economics and Health Care Research publishes a consensus paper on the possibilities and opportunities of the Humedics LiMAx liver function test in clinical application
Independent Health Technology Assessment (HTA) confirms: The LiMAx Liver Function Test from Humedics GmbH has both clinical and health economic advantages
Humedics LiMAx test: Inter-disciplinary expert panel defines indicators and recommendations for clinical application of the LiMAx liver function test
British NICE Institute: Positive assessment of the Humedics LiMAx® test
Independent trial shows accurate staging of liver fibrosis with the LiMAx® test
Safer liver resection: Perioperative assessment of liver function with the LiMAx® test shortens hospital stay and reduces complications after liver surgery
The LiMAx® liver capacity test is now commercially available in Germany, Austria and the UK
Humedics receives UK Marketing Authorization for its diagnostic agent, LiMAxetin®, and thus achieves full market clearance for the LiMAx® maximum liver capacity test in the UK, - the company’s first in Europe!
The LiMAx® test is now commercially available in the UK
read more Humedics receives UK Marketing Authorization for its diagnostic agent, LiMAxetin®, and thus achieves full market clearance for the LiMAx® maximum liver capacity test in the UK, - the company’s first in Europe!